BPC-157 and Tissue Repair: What the Preclinical Literature Shows
An overview of preclinical evidence describing how the pentadecapeptide BPC-157 has been studied for tendon, ligament, and gastrointestinal repair in animal models.
BPC-157 is a synthetic pentadecapeptide derived from a sequence identified in human gastric juice. The bulk of the published literature consists of preclinical animal studies investigating its effects on soft-tissue healing, gastrointestinal protection, and modulation of inflammatory pathways.
Reported mechanisms in the open-access literature include upregulation of growth factor signaling, modulation of nitric oxide pathways, and angiogenic effects that may support repair after injury. Human clinical trial data remain limited, and any therapeutic use should be considered investigational and supervised by a qualified clinician.
Key takeaways
- Most BPC-157 evidence is preclinical, not from large human trials.
- Proposed mechanisms involve angiogenesis and growth factor signaling.
- Clinical use should always be physician-supervised.
Source
PubMed Central (PMC)Educational only. Not medical advice. SEIVA protocols are prescribed only after physician review and telehealth consultation.